Profund Advisors LLC Has $3.97 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

Profund Advisors LLC grew its position in DexCom, Inc. (NASDAQ:DXCM) by 1.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,972 shares of the medical device company’s stock after purchasing an additional 656 shares during the period. Profund Advisors LLC’s holdings in DexCom were worth $3,965,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of DXCM. Gilbert & Cook Inc. raised its holdings in shares of DexCom by 8.2% in the fourth quarter. Gilbert & Cook Inc. now owns 3,431 shares of the medical device company’s stock valued at $426,000 after purchasing an additional 261 shares during the last quarter. 9258 Wealth Management LLC bought a new stake in DexCom during the 4th quarter worth about $286,000. Dimensional Fund Advisors LP lifted its position in DexCom by 6.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 647,172 shares of the medical device company’s stock worth $80,308,000 after buying an additional 39,786 shares in the last quarter. Avantax Advisory Services Inc. bought a new position in shares of DexCom in the 4th quarter valued at about $330,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of DexCom in the fourth quarter valued at about $284,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Down 2.1 %

DXCM opened at $70.43 on Friday. The stock has a fifty day moving average of $78.19 and a 200-day moving average of $109.54. The company has a market capitalization of $28.01 billion, a P/E ratio of 45.44, a P/E/G ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the company earned $0.34 EPS. The business’s revenue was up 15.3% on a year-over-year basis. On average, equities analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,483 shares of company stock worth $201,708. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on DXCM. Baird R W downgraded DexCom from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 26th. Piper Sandler reissued an “overweight” rating and issued a $90.00 target price on shares of DexCom in a research note on Monday, August 26th. BTIG Research dropped their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Barclays cut their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Finally, Oppenheimer lowered their price objective on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $112.25.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.